Literature DB >> 1620814

Mortality in systemic sclerosis (scleroderma).

P Lee1, P Langevitz, C A Alderdice, M Aubrey, P A Baer, M Baron, D Buskila, J P Dutz, I Khostanteen, S Piper.   

Abstract

Two hundred and thirty-seven patients with systemic sclerosis were followed prospectively in a scleroderma clinic. The overall 3, 6, and 9-year survival rates were 86, 76 and 61 per cent respectively. Renal, cardiac and pulmonary disease, and older age at enrollment were adverse prognostic factors associated with reduced survival. There were no significant differences in survival between males and females or in patients with restricted compared to those with diffuse skin thickening. Death from systemic sclerosis was most frequently due to pulmonary hypertension, with fewer than expected deaths from renal or cardiac causes. Twenty-eight per cent of deaths were due to causes unrelated to systemic sclerosis, most commonly cancer and ischaemic heart disease, and in older patients.

Entities:  

Mesh:

Year:  1992        PMID: 1620814

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  24 in total

Review 1.  Primary pulmonary hypertension.

Authors:  A J Peacock
Journal:  Thorax       Date:  1999-12       Impact factor: 9.139

Review 2.  A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism.

Authors:  E Hachulla; J G Coghlan
Journal:  Ann Rheum Dis       Date:  2004-09       Impact factor: 19.103

3.  Predictors of survival in 171 patients with systemic sclerosis (scleroderma).

Authors:  Z Nagy; L Czirják
Journal:  Clin Rheumatol       Date:  1997-09       Impact factor: 2.980

4.  Implantable cardioverter defibrillator to prevent sudden cardiac death in a patient with systemic sclerosis: A clinical case.

Authors:  Fabio Marsico; Gianluigi Savarese; Celestino Sardu; Cristoforo D'Ascia; Donatella Ruggiero; Laura Casaretti; Valentina Parisi; Francesca Musella; Elisabetta Pirozzi; Roberto Formisano; Teresa Losco; Pasquale Perrone Filardi
Journal:  J Cardiol Cases       Date:  2012-03-31

5.  Effect of mycophenolate sodium in scleroderma-related interstitial lung disease.

Authors:  Carmen Pilar Simeón-Aznar; Vicent Fonollosa-Plá; Carles Tolosa-Vilella; Albert Selva-O'Callaghan; Roser Solans-Laqué; Miquel Vilardell-Tarrés
Journal:  Clin Rheumatol       Date:  2011-09-01       Impact factor: 2.980

6.  Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma.

Authors:  Robyn T Domsic; Tatiana Rodriguez-Reyna; Mary Lucas; Noreen Fertig; Thomas A Medsger
Journal:  Ann Rheum Dis       Date:  2010-08-02       Impact factor: 19.103

Review 7.  Drug treatment of scleroderma.

Authors:  C Leighton
Journal:  Drugs       Date:  2001       Impact factor: 9.546

8.  Clinical and laboratory profiles of 136 systemic sclerosis patients with and without echocardiographically detected pulmonary hypertension.

Authors:  J-H Tao; Y-N Wan; Y Zhang; J-W Yan; Y-J Wang; G-J Yang; X-P Li; D-Q Ye; J Wang
Journal:  Z Rheumatol       Date:  2015-02       Impact factor: 1.372

9.  Survival and causes of death in systemic sclerosis patients: a single center registry report from Iran.

Authors:  Hadi Poormoghim; Elham Andalib; Arash Jalali; Afshin Ghaderi; Ali Ghorbannia; Nazanin Mojtabavi
Journal:  Rheumatol Int       Date:  2016-04-09       Impact factor: 2.631

Review 10.  Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.

Authors:  Peter Kabunga; Gerry Coghlan
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.